IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21

A. P. Moroz(Roswell Park Comprehensive Cancer Center), Cheryl Eppolito(Roswell Park Comprehensive Cancer Center), Qingsheng Li(Roswell Park Comprehensive Cancer Center), Jianming Tao(Roswell Park Comprehensive Cancer Center), Christopher H. Clegg(Immungenetics (Germany)), Protul Shrikant(Roswell Park Comprehensive Cancer Center)
The Journal of Immunology
July 1, 2004
Cited by 264Open Access
Full Text

Abstract

Cytokines that use the common receptor gamma-chain for regulating CD8(+) T cell responses to Ag include IL-2, IL-15, and the recently identified IL-21. The ability of these cytokines to regulate antitumor activity in mice has generated considerable interest in understanding their mode of action. In this study we compare the abilities of IL-2, IL-15, and IL-21 to stimulate immunity against tumors in a syngeneic thymoma model. Durable cures were only achieved in IL-21-treated mice. By monitoring both endogenous and adoptively transferred tumor Ag-specific CD8(+) T cells, it was determined that IL-21 activities overlap with those of IL-2 and IL-15. Similar to IL-2, IL-21 enhanced Ag activation and clonal expansion. However, unlike IL-2 treatment, which induces activation-induced cell death, IL-21 sustained CD8(+) T cell numbers long term as a result of increased survival, an effect often attributed to IL-15. These findings indicate that the mechanisms used by IL-21 to promote CD8(+) T cell responses offer unique opportunities for its use in malignant diseases and infections.


Related Papers

No related papers found

Powered by citation graph analysis